Obinutuzumab

Cytostatic · Monoclonal antibody

Indications

In combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Dosage

Children: Recommended dose for 6 cycles (28 day cycles). 100 mg on day 1 cycle 1, 900 mg on day 2 cycle 1, 1000 mg on day 8 and 5 of cycle 1, 1000 mg on day 1 of cycles 2-6.

Administration

Dilute and administer as IV infusion. Do not administer as an IV push or bolus. Do not mix obinutuzumab with other drugs. Reconstitution: Dilute into a 0.9% sodium chloride PVC or non-PVC polyolefin infusion bag. Do not use other diluents such as dextrose (5%). Preparation of solution for infusion on day 1 (100 mg) and day 2 (900 mg) of cycle 1, withdraw 40 mL of drug solution from the vial. Dilute 4 mL (100 mg) of drug into a 100 mL 0.9% NaCl infusion bag for immediate administration. Dilute the remaining 36 mL (900 mg) into a 250 mL 0.9% NaCl infusion bag at the same time for use on day 2. Preparation of solution for infusion on day 8 and 15 of cycle 1 and day 1 cycles 26, withdraw 40 mL of drug solution from the vial. Dilute 40 mL (1000 mg) into a 250 mL 0.9% NaCl infusion bag. Mix diluted solution by gentle inversion. Do not shake or freeze. Stability: Store at 2°C to 8°C (36°F to…

Adverse Effects

Infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, and musculoskeletal disorder.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Precautions: Infusion reactions, neutropenia, thrombocytopenia, tumor lysis syndrome, immunization.

Pharmacokinetics

Half-life elimination: Terminal: 25-36 days.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.